Clinical trial · Observational
Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC
Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant PD-1 Inhibitors Following Liver Resection in Hepatocellular Carcinoma: A Multicenter Cohort and Multiomics Study
NCT06461936CI-TRIAL-00077996unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC positive patients have a higher rate of postoperative recurrence. However, it is not clear how the surgical prognosis of VETC-positive patients can be improved.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adjuvant Therapy | — | UNRESOLVED | — |
| HCC | — | UNRESOLVED | — |
| Immunotherapy | — | UNRESOLVED | — |
| Recurrence | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lenvatinib | Drug | Lenvatinib | ALIAS |
| Sintilimab | Drug | Sintilimab | ALIAS |
Design
Arms and outcomes
Arms (3)
- label
- Active Surveillance Group（AC）
- description
- Patients in AC group received no adjuvant therapy after liver resection.
- label
- Adjuvant sintilimab group（AS）
- description
- Patients in AS group received adjuvant sintilimab after liver resection.
- interventionNames
- Drug: Sintilimab
- label
- Adjuvant sintilimab plus Lenvatinib group （ASL）
- description
- Patients in ASL group received adjuvant sintilimab plus lenvatinib therapy after liver resection.
- interventionNames
- Drug: Sintilimab
- Drug: Lenvatinib
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Underwent radical hepatectomy * No preoperative treatment * Pathological confirmed HCC * High-risk recurrent HCC * Not receiving any adjuvant therapy or receiving adjuvant therapy with PD-1 monotherapy or receiving adjuvant therapy with PD-1 monotherapy in combination with Lenvatinib after surgery * Evaluable wax block tissue as well as complete clinical information Exclusion Criteria: * Distant metastasis * No available wax blocks
References
Publications (0)
Data not yet available
No reference posted for this study.